Tirzepatide vs. Semaglutide: How They Work for Weight Loss

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on peptides & glp-1. Browse all Peptides & GLP-1 education

Tirzepatide and semaglutide are the two most-discussed weight-management medications, and readers comparing them usually want the same thing: a clear, neutral explanation of how they differ mechanically and what the research shows. Both act on the GLP-1 pathway, but they are not the same molecule. This article covers the mechanisms, the head-to-head evidence, side effects, and the genetic context that sits upstream of either choice.

Semaglutide vs. tirzepatide at a glance

Semaglutide is a single-target GLP-1 receptor agonist, sold under branded reference products including Ozempic and Wegovy. Tirzepatide is a dual GIP and GLP-1 receptor agonist, sold under Mounjaro and Zepbound. Both are incretin-based and both are FDA-approved for chronic weight management, but tirzepatide engages a second incretin receptor that semaglutide does not.

How each medication works

GLP-1 is an incretin hormone released after eating that promotes satiety, slows gastric emptying, and supports glucose-dependent insulin release. Semaglutide mimics GLP-1 at that single receptor. Tirzepatide adds activity at the GIP receptor, a second incretin target involved in insulin secretion and fat metabolism. The dual mechanism is the central structural difference between the two compounds and the reason they are studied as distinct agents rather than interchangeable ones.

What the head-to-head research shows

Both compounds have large trial programs — the STEP trials for semaglutide and the SURMOUNT and SURPASS trials for tirzepatide. In 2025, the SURMOUNT-5 trial directly compared the two in adults with obesity and reported greater average weight reduction with tirzepatide over the study period. Trial populations, durations, and endpoints vary, so results are best read as what each agent achieved in its studied context rather than as a universal ranking. Individual outcomes differ.

FDA status, formats, and access

Semaglutide is FDA-approved for type 2 diabetes and for chronic weight management, and is available in injectable and oral forms. Tirzepatide is FDA-approved for type 2 diabetes and for chronic weight management, currently in injectable form for the branded reference products. PlexusDx offers both through its Weight Management Protocols, dispensed by licensed 503A compounding pharmacies. This article does not provide dosing or titration guidance — a licensed provider sets that individually.

Side effects and tolerability

Both medications share a similar side-effect profile driven by their shared GLP-1 mechanism: gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation are the most common in labeling for both. Both carry a boxed warning related to thyroid C-cell tumors in rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pancreatitis and gallbladder concerns are noted for each.

The shared genetic architecture: GLP1R and GIPR

Because both compounds act on the incretin system, the same genes sit upstream of both. GLP1R encodes the GLP-1 receptor that both semaglutide and tirzepatide engage, while GIPR encodes the GIP receptor that tirzepatide additionally targets. Common variants in these genes are studied for their influence on receptor signaling, insulin secretion, and appetite regulation — the shared pathway biology that applies whichever agent a person and their provider eventually discuss.

PlexusDx offers both Semaglutide and Tirzepatide through its Weight Management Protocols. The upstream insight is what sets the approach apart. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including variants in GLP1R and GIPR that shape your baseline GLP-1 pathway biology. It reports on pathways, not on which medication will work for you. Knowing that profile before choosing a protocol is the "test before you invest" approach.

Frequently Asked Questions

How does tirzepatide differ from semaglutide mechanically?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, while semaglutide targets the GLP-1 receptor alone. Both slow gastric emptying and promote satiety through the GLP-1 pathway, but tirzepatide adds activity at the GIP receptor. That second incretin target is the core mechanical difference between the two compounds.

Which one is more effective for weight loss?

Trial populations and endpoints differ, so a single ranking oversimplifies. The 2025 SURMOUNT-5 head-to-head reported greater average weight reduction with tirzepatide over the study period, but individual results vary. Effectiveness depends on many factors a licensed provider weighs, which is why the decision is individual rather than universal.

Are the side effects different?

The side-effect profiles are broadly similar because both act on the GLP-1 pathway. Gastrointestinal effects such as nausea, diarrhea, and constipation are the most common for each. Both carry the same boxed thyroid warning and similar contraindications. A provider reviews your history to weigh tolerability before recommending either.

Can genetic testing predict which one is right for me?

No. The Precision Peptide Genetic Test does not predict response to semaglutide, tirzepatide, or any specific medication. It analyzes shared pathway variants such as GLP1R and GIPR that shape your baseline GLP-1 biology. That context supports an informed conversation with your provider — it does not select a drug for you.

Compare your options: explore the PlexusDx Weight Management Protocols for both Semaglutide and Tirzepatide from licensed 503A compounding pharmacies, or start upstream with the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Disclaimer: This article is educational. PlexusDx offers both Semaglutide and Tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.